Terazosin Capsule
Product Images NDC 71610-478

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71610-478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 1 mg (71610 0478 60)

Label for Terazosin HCl USP capsules, 1 mg strength, with a package size of 90 capsules. The label includes storage instructions to keep the product between 20-25 degrees Celsius and to store in a tight light-resistant container. The manufacturer is Jubilant Cadista Pharmaceuticals Inc, Salisbury, MD, and the labeler is Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN 38501. The product is for oral use and prescription only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride showing its molecular components including aromatic rings, amino group, ether linkages, and hydrochloride salt.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This image contains two line charts. The left chart shows the mean change in total symptom score from baseline over a 3-month period comparing Terazosin and placebo groups. The right chart illustrates the mean increase in peak flow rate (mL/sec) from baseline over the same timeframe, also comparing Terazosin and placebo groups. Each chart includes sample sizes (N) and error bars.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph showing mean change from baseline over time in months, with values plotted from month 0 to month 30 and a decreasing trend depicted. Data points are marked with circles and some points indicated with asterisks, suggesting statistically significant changes at those times.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph depicting the mean change from baseline in mL/sec over time in months, from 0 to 30 months. The data points show an increase over time, with a marked change during the first few months and sustained levels thereafter. Error bars are included at each point, and asterisks denote statistically significant changes at multiple time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.